226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred

Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House's investment in biotech, a bellwether IPO, and the latest twist in the Merck-Seagen saga.